Search research articles
Contact Us
Filters
Showing results (121-130 of 139) with videos related to
Page
of 14
Sort By:
Oncology Letters
|
January 23, 2020
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab
Valerio Nardone, Paolo Tini, Pierpaolo Pastina, et al.
Diagnostics (Basel, Switzerland)
|
May 27, 2023
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial
Valerio Nardone, Maria Paola Belfiore, Marco De Chiara, et al.
Frontiers in Oncology
|
October 3, 2022
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
Antonella Fameli, Valerio Nardone, Mojtaba Shekarkar Azgomi, et al.
Cancer Biology & Therapy
|
October 30, 2016
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse
Valerio Nardone, Cirino Botta, Michele Caraglia, et al.
Translational Oncology
|
April 5, 2026
Proof-of-concept study of clinical use of blood-based MAVS biosensor in predicting immunotherapy response in SCLC patients
Luisa Amato, Ines Tavoletta, Caterina De Rosa, et al.
Journal of Thoracic Disease
|
December 10, 2017
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients
Pierpaolo Pastina, Valerio Nardone, Stefania Croci, et al.
Oncoimmunology
|
August 29, 2024
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma
Vincenzo De Falco, Stefania Napolitano, Renato Franco, et al.
Cells
|
August 29, 2020
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
Pierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
Journal of Translational Medicine
|
November 24, 2022
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
Carminia Maria Della Corte, Vincenza Ciaramella, Kavya Ramkumar, et al.
Life (Basel, Switzerland)
|
November 27, 2021
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
Valerio Nardone, Rocco Giannicola, Diana Giannarelli, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 139) with videos related to
Sort By:
Page
of 14
Oncology Letters
|
January 23, 2020
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab
Valerio Nardone, Paolo Tini, Pierpaolo Pastina, et al.
Diagnostics (Basel, Switzerland)
|
May 27, 2023
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial
Valerio Nardone, Maria Paola Belfiore, Marco De Chiara, et al.
Frontiers in Oncology
|
October 3, 2022
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
Antonella Fameli, Valerio Nardone, Mojtaba Shekarkar Azgomi, et al.
Cancer Biology & Therapy
|
October 30, 2016
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse
Valerio Nardone, Cirino Botta, Michele Caraglia, et al.
Translational Oncology
|
April 5, 2026
Proof-of-concept study of clinical use of blood-based MAVS biosensor in predicting immunotherapy response in SCLC patients
Luisa Amato, Ines Tavoletta, Caterina De Rosa, et al.
Journal of Thoracic Disease
|
December 10, 2017
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients
Pierpaolo Pastina, Valerio Nardone, Stefania Croci, et al.
Oncoimmunology
|
August 29, 2024
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma
Vincenzo De Falco, Stefania Napolitano, Renato Franco, et al.
Cells
|
August 29, 2020
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
Pierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
Journal of Translational Medicine
|
November 24, 2022
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
Carminia Maria Della Corte, Vincenza Ciaramella, Kavya Ramkumar, et al.
Life (Basel, Switzerland)
|
November 27, 2021
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
Valerio Nardone, Rocco Giannicola, Diana Giannarelli, et al.
Page
of 14